• Phenothiazines Promote Macrophage Antibacterial Activity via

  2026-05-03

  This study reveals that phenothiazines, including perphenazine, boost macrophage antibacterial defenses by promoting reactive oxygen species (ROS) accumulation and autophagy. These findings suggest a potential host-directed therapy approach for combating intracellular bacterial infections and antibiotic resistance.

• Streptozotocin in Diabetes Research: Protocols & Innovations

  2026-05-02

  Streptozotocin (STZ) is the gold-standard tool for experimental diabetes mellitus induction, enabling precise modeling of β-cell apoptosis and neuroimmune complications. This guide details optimized workflows, troubleshooting strategies, and the translational impact of cutting-edge research leveraging STZ from APExBIO.

• Midecamycin: Applied Protocols for Gram-Positive Inhibition

  2026-05-02

  Midecamycin, a 16-membered acetoxy-substituted macrolide antibiotic, delivers precise and robust inhibition of Gram-positive bacteria by targeting bacterial protein synthesis. This article translates current research and quantitative protocols into practical workflows, troubleshooting strategies, and comparative advantages for microbiology laboratories seeking advanced antibacterial control.

• WZ4003: Precision NUAK1/2 Inhibitor Workflows in Cancer & Ta

  2026-05-01

  WZ4003 is a best-in-class NUAK1/2 inhibitor with nanomolar potency, enabling researchers to dissect cell migration, proliferation, and tau phosphorylation with high specificity. This article translates recent landmark findings and validated experimental workflows into actionable guidance for optimizing cancer and neurodegeneration assays using WZ4003 from APExBIO.

• Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal S

  2026-04-30

  Recent research reveals that moxidectin, beyond its veterinary antiparasitic role, dramatically enhances polyene antifungal action against Candida albicans by upregulating ergosterol biosynthesis. This article translates these findings into actionable, experiment-ready workflows with troubleshooting insight, making APExBIO's high-purity moxidectin an indispensable tool for modern antifungal assay development.

• TBK1 Inhibition Alleviates Painful Diabetic Neuropathy via M

  2026-04-30

  Liao et al. (2024) identify TANK-binding kinase 1 (TBK1) as a pivotal mediator of painful diabetic neuropathy (PDN) through its regulation of microglial pyroptosis. The study demonstrates that both genetic and pharmacological TBK1 inhibition reduce neuroinflammation and pain, offering a mechanistic foundation for targeting TBK1 in PDN therapy.

• Hydrocortisone in Bench Research: Protocols, Models, and Tro

  2026-04-29

  Hydrocortisone stands as the gold-standard glucocorticoid hormone for dissecting stress, inflammation, and neuroprotection in both cellular and animal research models. This guide distills best practices for experimental workflows, data-driven troubleshooting, and integrating hydrocortisone’s unique properties into state-of-the-art biomedical studies.

• HyperFluor 488 Goat Anti-Mouse IgG: Amplified Detection in V

  2026-04-29

  The HyperFluor 488 Goat Anti-Mouse IgG (H+L) Antibody delivers unmatched sensitivity for detecting subtle endothelial changes in radiation injury models. This fluorescently labeled secondary antibody, supplied by APExBIO, enables robust signal amplification and reproducibility across immunofluorescence, flow cytometry, and western blotting workflows.

• PCMT1 Identified as Metastatic Driver in Ovarian Cancer via

  2026-04-28

  Zhang et al. leveraged a genome-wide CRISPR/Cas9 screen to pinpoint PCMT1 as a pivotal mediator of anoikis resistance and metastatic progression in ovarian cancer. Their mechanistic and in vivo validation highlights PCMT1 as a potential therapeutic target, with broader implications for understanding ECM-driven metastasis.

• 2-Deoxy-D-glucose: Applied Glycolysis Inhibition Workflows

  2026-04-28

  2-Deoxy-D-glucose (2-DG) from APExBIO empowers researchers to dissect cancer metabolism, viral replication, and immunometabolic signaling with quantitative rigor. This guide translates cutting-edge metabolic reprogramming findings into actionable protocols and troubleshooting strategies, ensuring reproducible results in even the most challenging experimental systems.

• G007-LK Tankyrase 1/2 Inhibitor: Practical Insights for Lab

  2026-04-27

  This article provides evidence-based guidance for deploying G007-LK tankyrase 1/2 inhibitor (SKU B5830) in cell viability and pathway modulation assays. Scenario-driven Q&A blocks address experimental challenges, protocol optimization, and product reliability, ensuring researchers can leverage G007-LK for robust Wnt/β-catenin and Hippo pathway research.

• Nitrocefin in β-Lactamase Assays: Precision Tools for Resist

  2026-04-27

  Explore how Nitrocefin, a chromogenic cephalosporin substrate, enables precise and real-time β-lactamase activity measurement for advanced antibiotic resistance research. This article delivers a unique, protocol-focused analysis guiding optimal assay deployment.

• Microbiota–Tryptophan–AhR Axis in Intestinal Repair for UC

  2026-04-26

  Li et al. (2026) reveal that Huangqin decoction (HQD) repairs ulcerative colitis (UC) through a novel microbiota–tryptophan metabolism–AhR–intestinal stem cell axis. Their findings highlight the central role of microbial metabolites in activating aryl hydrocarbon receptor (AhR) signaling, promoting stem cell differentiation, and restoring mucosal integrity—providing new mechanistic insight relevant to both mucosal repair and environmental toxicology research.

• FPH1 (BRD-6125): Optimizing Hepatocyte Proliferation Workflo

  2026-04-25

  FPH1 (BRD-6125) uniquely drives functional, donor-independent expansion of human hepatocytes—crucial for high-throughput drug screening and regenerative medicine. Discover how protocol refinements with APExBIO’s FPH1 unlock reproducible, scalable primary hepatocyte and iHeps cultures.

• Bifendate (DDB): CYP3A4 Modulation and Precision Hepatoprote

  2026-04-24

  Explore Bifendate (DDB) as a hepatoprotection agent with unique CYP3A4 modulation, supported by pharmacogenetic insights. This article reveals how genotype-dependent drug interactions shape experimental and clinical decisions.

444 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page